PolyPid Ltd. (PYPD) has released an update.
PolyPid Ltd. has reached a milestone by enrolling the 200th patient in the SHIELD II Phase 3 trial, aiming to prevent surgical site infections with its product D-PLEX100. The trial is on track, with an interim analysis expected in mid-2024 and top-line results anticipated in the second half of 2024. Financially supported by a recent $16 million private financing, PolyPid could secure an additional $19 million if interim results are positive, which would support its New Drug Application submission process.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
